The bill is expected to have significant implications for state laws governing healthcare and pharmaceutical spending. By requiring a thorough comparison of costs, it aims to ensure that the appointed PBM operates efficiently and effectively in managing prescription drug expenditures. If the assessment reveals no cost savings, the commissioner can choose not to utilize a reverse auction for selecting future PBM contracts, introducing a new layer of operational flexibility in the procurement process.
Summary
SF3854 is a bill relating to state government that clarifies requirements for pharmacy benefit managers (PBM). It aims to enhance the accountability of PBMs by mandating the commissioner of management and budget to compare actual prescription drug costs under the current PBM contract with projected costs under a previous contract. This comparison is to be conducted with the help of an actuarial consultant, ensuring transparency and accuracy in evaluating the effectiveness of the PBM in reducing prescription costs for the state.
Contention
Notable points of contention may arise around the transparency of the processes and potential conflicts of interest. The bill mandates the actuarial consultant to take measures to avoid conflicts, which indicates a recognition of possible bias or inefficiencies within the current system. Furthermore, there may be concerns regarding how cost savings are defined and measured, which could impact the future selection of pharmacy benefit managers, creating a debate over the principles guiding public health management and fiscal responsibility.
Pharmacy benefit managers and health carriers usage of prescription drug rebates and other compensation requirement to benefit covered persons provision
Article V Convention; process for appointing commissioners and alternate commissioners to represent the State of Alabama at Article V Convention established